Novo Holdings has completed its $16.5 billion acquisition of Catalent, the contract drug manufacturer said on Wednesday, days ...

Novo Holdings has completed the previously announced acquisition of Catalent in a $16.5bn all-cash transaction. The European ...

StockNews.com began coverage on shares of Catalent (NYSE:CTLT – Free Report) in a research report sent to investors on Friday ...

Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have been given an average rating of “Hold” by the seven analysts that are presently covering the company, Marketbeat.com reports. Seven analysts ...

Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life ...

BRUSSELS (Reuters) -Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see any ...

The latest announcement is out from Catalent ( (CTLT) ).

Catalent (NYSE:CTLT) rose 1.6% after a report that the contract drug manufacturer's $16.5 billion sale to Novo Holdings could close as soon as Monday. The US Federal Trade Commission doesn't ...

Catalent is an attractive buyout target for Novo Holdings — which owns 77% of the voting shares in the drugmaker — because it is currently a subcontractor that helps manufacture Wegovy ...

SOMERSET, N.J. & COPENHAGEN, Denmark, December 06, 2024--(BUSINESS WIRE)--Catalent, Inc. ("Catalent," NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients ...

Novo Holdings, the controlling shareholder of Novo Nordisk , on Wednesday sealed its $16.5 billion deal for Catalent , as the Danish drugmaker looks to boost supplies of its widely popular weight ...